Calgary Transit Is En-Route With Access-IS Ticket Validators
27.10.2020 12:00:00 EET | Business Wire | Press release
Access-IS, part of HID, the leading supplier of software agnostic ticket validators is excited to announce the integration of its VAL100 devices by Masabi. The integration is part of Masabi’s My Fare solution, a contactless mobile ticketing app for Calgary Transit that lets passengers buy tickets and passes anytime, anywhere, using their smartphones. It’s fast, easy, contactless and a safe way to pay and ride transit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027005015/en/
Access-IS VAL100 ticket validator alongside Masabi’s My Fare solution (Photo: Business Wire)
The My Fare app, which is powered by Masabi’s Justride platform and can be downloaded from the App Store and Google Play, allows riders of Calgary Transit services to purchase and use fare products such as regular monthly and day passes, airport boarding pass, and single ride tickets directly from their mobile device.
As part of the project over 1000 Access-IS VAL100 ticket validators have been installed across the bus network covering 155 routes. Passengers scan their dynamic and encrypted mobile passes on the devices when boarding the bus, with an audible beep and a colored screen identifying the ticket as valid for use. These validation units will help speed up boarding times making riding Calgary Transit services faster and safer by enabling contactless fare payment and validation. The validation units are powered by Masabi’s Justride Inspect software but also read NFC and contactless EMV (cEMV) technology, giving the agency the flexibility to turn on Account-Based Ticketing and other account-based tokens, if required.
“Calgarians, like citizens in towns and cities around the world, are using smartphones in almost all aspects of their day and made offering the option for riders to use their phone instead of a paper ticket a logical step for Calgary Transit,” said Brian Zanghi, CEO of Masabi. “The change in people’s behaviour brought about by the current requirement for social distancing has made mobile ticketing and the move towards a more contactless journey experience a must-have for transit agencies.”
The VAL100 combines barcode and NFC/RFID reading functionality to provide a single point of presentation for tickets and travel passes – whether presented on a paper ticket, smartcard or mobile phone. It is also available with EMV Level 2 certification, allowing for applications where contactless payments are required. It offers PCI and SRED compliance for contactless payments using VISA, MasterCard, AMEX and Discover payment schemes. It features clear visual and audio passenger feedback, a robust design and a wide range of connection options for installation flexibility.
Speaking about the installation, Bryan Cunningham Regional Sales Manager (Americas) at Access-IS said “It’s always a pleasure to work with Masabi to deliver a ticketing and fare payment solution focused on providing the very best passenger experience whilst protecting the transits agency’s ability to manage fare revenue.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005015/en/
Contact information
Andrew Covey
+44(0)118-966-3333
Andrew.Covey@access-is.com
www.access-is.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 15:05:00 EEST | Press release
Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifestations,” said David Weinreich, Global Head of R&D, Merck. “With enpatoran, we aim to target the underlying drivers of lupus and redefine how to approach the disease by understanding both visible skin manifestations and systemic activity.” Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor designed to modulate pathways central to lupus-related inflammatio
The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 15:00:00 EEST | Press release
The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i
Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 15:00:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are: Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of Michael Kors’ strongest performance periods. Titan of Europe: Ash Cummings, Ecommerce Fraud Prevention Manager, Gymshark A
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 14:00:00 EEST | Press release
CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monit
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint ® and BluePrint ® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 14:00:00 EEST | Press release
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors – a group that typically has favorable outcomes. MammaPrint (MP) identified a High Risk 2 (H2) subset, representing 10% of all patients and 5% of those
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom